Eli Lilly And Company

This study tests the long-term safety of an experimental oral drug called orforglipron in adults with type 2 diabetes whose blood sugar is not well controlled by diet, exercise, or other diabetes pills. Participants take the drug once daily for about a year, and researchers monit…

This completed Phase 4 study compared the safety of baricitinib (a daily pill) to TNF inhibitors (injections) in over 2,600 adults with rheumatoid arthritis. The main goal was to see if baricitinib had a higher risk of blood clots. Participants had to be at least 60, have a histo…

This early-stage trial tested a new drug, LY3849891, in 115 people with fatty liver disease who carry a specific gene variant (PNPLA3 I148M). The main goal was to check safety and how the body processes the drug. Researchers also looked at changes in liver fat and inflammation us…

This phase 2 study tested a new drug called eloralintide (LY3841136) for weight management in 263 adults with obesity or overweight. Participants received either the drug or a placebo for about 64 weeks. The main goal was to see how much weight they lost after 48 weeks. Results w…

This study tests whether adding a weight-loss drug (tirzepatide) to a standard psoriasis treatment (ixekizumab) helps people with moderate-to-severe plaque psoriasis who are also overweight or obese. About 250 adults will receive either ixekizumab alone or both drugs together for…

This completed Phase 2 trial tested an oral drug called LY3372689 in 327 people with early symptomatic Alzheimer's disease. The goal was to see if the drug could safely slow down declines in thinking and daily living skills compared to a placebo. The study focused on participants…

This study tested the drug mirikizumab in 172 adults with moderate-to-severe ulcerative colitis who still had bowel urgency despite other treatments. The main goal was to see if the drug reduces the sudden, urgent need to use the bathroom. Participants were followed for 36 weeks …

This phase 3 trial tests whether a daily oral drug called orforglipron can help people with obesity or overweight maintain weight loss they achieved with injectable tirzepatide or semaglutide. About 376 participants who completed a prior weight-loss study will receive orforglipro…

This study tested the drug mirikizumab in 63 children aged 2 to 17 with moderate-to-severe ulcerative colitis, a chronic bowel disease. The goal was to see if the drug could help control the disease and improve symptoms. All children received the drug, and researchers measured re…

This large Phase 3 trial tested a once-weekly injection called retatrutide in over 2,300 adults with obesity or overweight who do not have type 2 diabetes. The study also looked at how the drug affects knee osteoarthritis and obstructive sleep apnea. Participants received either …

This early-phase study tested an experimental drug called LY3537982 in 12 Chinese patients with advanced solid tumors that have a specific KRAS G12C mutation. The main goal was to measure how the drug moves through the body and to check its safety. Researchers also looked for sig…

This early-stage study tested an oral drug called LY3502970 in 68 adults with type 2 diabetes. The main goal was to check safety and side effects, while also measuring how the drug moves through the body and affects blood sugar. Participants took the drug or a placebo for up to 1…

This study tested an oral drug called LY3502970 in 72 healthy overweight and obese adults to see if it is safe and how the body processes it. Participants took the drug by mouth, and researchers monitored side effects and drug levels in the blood over up to 42 days. The goal was …

This study looked at whether starting tirzepatide, a once-weekly injection for type 2 diabetes, before Ramadan helps people manage their blood sugar safely while fasting. 166 adults with uncontrolled diabetes who planned to fast took part. Researchers measured changes in blood su…

This study tested an experimental oral drug called LY3871801 in 164 adults with moderately-to-severe rheumatoid arthritis. The goal was to see if it reduces joint swelling and pain better than a placebo. The trial is complete, and results will help decide if further testing is wa…

This large Phase 3 study tested an experimental drug called remternetug in over 1,600 people with early symptoms of Alzheimer's disease. The main goal was to see if the drug could safely clear amyloid plaques from the brain, a hallmark of Alzheimer's. Participants received either…

This study tested a once-daily medication called LY3549492 to help adults with obesity or overweight lose weight. About 288 participants took either the drug or a placebo for around one year. The main goal was to see how much weight they lost and how safe the treatment was.

This study tested whether mirikizumab can help people with moderate to severe ulcerative colitis stay in remission (symptom-free) after they had already responded to an initial treatment. About 1,300 adults who completed a prior induction study were randomly assigned to receive m…

This study tested whether adding a weight-loss drug (tirzepatide) to a standard arthritis drug (ixekizumab) helps people with psoriatic arthritis who are overweight or obese. 279 adults with active psoriatic arthritis and a BMI of 27 or higher took part. The goal was to see if th…

This study tested a drug called ramucirumab, given with standard chemotherapy, for children and young adults with a rare cancer called desmoplastic small round cell tumor (DSRCT) that had come back or not responded to treatment. The goal was to see if the combination could slow t…

This study looked at whether adding a second drug (mibavademab) to the weight-loss medication tirzepatide helps adults with obesity lose more weight than tirzepatide alone. About 392 participants with a BMI between 30 and 40 took part. The goal was to measure changes in body weig…

This study tested a new drug called Mazdutide to help adults with obesity or overweight lose weight. 179 participants took either the drug or a placebo for about 62 weeks. The main goal was to see how much weight they lost after 32 weeks, with a focus on safety and effectiveness.

This study tested a once-daily pill called orforglipron in 559 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. The pill was compared to a placebo (a dummy pill) over about 54 weeks to see if it safely lowers blood sugar levels. Th…

This study tested a once-daily pill called orforglipron against insulin glargine in nearly 2,750 adults with type 2 diabetes, obesity or overweight, and increased cardiovascular risk. The main goal was to see if orforglipron could reduce major heart events like heart attacks or s…

This study tested baricitinib, an anti-inflammatory pill, in 784 adults with severe or very severe alopecia areata, a condition causing extensive hair loss. Participants received either baricitinib or a placebo for up to 52 weeks. The main goal was to see if baricitinib could reg…

This study tested the drug baricitinib in 606 adults with severe or very severe alopecia areata, a condition causing significant hair loss. Participants took either baricitinib or a placebo pill daily for up to 36 weeks. The main goal was to see if baricitinib could regrow enough…

This study looked at how a new medicine, LY3209590, is processed in the bodies of 15 children with type 2 diabetes. Each child received one dose, and researchers measured the drug levels in their blood over time. The goal was to understand how the drug is absorbed and removed, no…

This study tested whether the drug tirzepatide, given once weekly, can help people with obesity or overweight maintain weight loss they achieved during a prior diet period. About 441 participants took either tirzepatide or a placebo for 60 weeks. The goal was to see if the drug c…

This study tested a new oral drug called LY3549492 in 92 Japanese volunteers, some with type 2 diabetes and some healthy. The main goal was to check safety and how the body processes the drug. Participants took multiple doses over several weeks, and researchers monitored side eff…

This study tested a drug called donanemab (LY3002813) in 272 people with early symptoms of Alzheimer's disease. The goal was to see if the drug is safe and can slow down memory loss and daily functioning problems. Participants received either the drug or a placebo, and researcher…

This study tested the drug lebrikizumab in 90 adults and teens with moderate-to-severe eczema who have skin of color. The goal was to see if the drug is safe and helps clear skin. Participants received injections over 24 weeks, and doctors measured improvement using a standard ec…

This study tested a new weekly medicine called retatrutide in 537 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either the medicine or a placebo for about 11 months. The goal was to see if retatrutide safel…

This study tested the safety and effectiveness of the drug abemaciclib combined with other cancer medicines in 47 children and young adults whose solid tumors (including neuroblastoma) had stopped responding to standard treatments. The goal was to find the best dose and see if th…

This early-stage study tested a new daily pill called LY3549492 in 36 Chinese adults with type 2 diabetes. The main goal was to check safety and side effects over about 18 weeks. Participants had diabetes for at least 6 months and were on diet, exercise, or stable metformin. This…

This early-stage study tested an oral drug called orforglipron in 120 adults with obesity or overweight (but without diabetes). The goal was to see how it changes body fat compared to a placebo over about 8 months. Researchers measured fat around organs, appetite, and weight. Thi…

This study tested a drug called lebrikizumab in 86 adults and teens with moderate-to-severe eczema who had already tried dupilumab. The goal was to see if lebrikizumab could safely improve their skin condition. Researchers measured how many participants achieved at least a 75% im…

This phase 2 study tested an oral drug called pirtobrutinib in 87 Chinese adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma who had already received standard treatments. The goal was to see how well the drug shrank tumors and to check f…

This early-stage study tests a new drug called eloralintide, alone or combined with tirzepatide, in 188 adults with overweight or obesity. The main goals are to check safety, side effects, and how the drugs move through the body. Participants receive weekly injections under the s…

This study tested whether adding a new drug (LY2875358) to the standard treatment erlotinib helps people with advanced non-small cell lung cancer that has a specific gene mutation. All 168 participants first took erlotinib alone for 8 weeks. Those whose cancer did not worsen were…

This phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.

This completed phase 3 trial tested two injectable weight loss drugs, tirzepatide and semaglutide, in 751 adults with obesity or overweight who also had weight-related health problems like high blood pressure. The study lasted about 74 weeks and measured how much weight participa…

This study tested a new drug (LY2157299) alone or combined with standard chemotherapy (lomustine) in 158 adults with recurrent glioblastoma, an aggressive brain cancer. The goal was to see if the new drug could help patients live longer or slow tumor growth compared to chemothera…

This study tested whether retatrutide, a medication being studied for weight loss, can help preserve kidney function in 146 adults who are overweight or obese and have chronic kidney disease (with or without type 2 diabetes). Participants received the drug or a placebo for about …

This early-stage study tested a single dose of the investigational drug eloralintide in 30 Chinese adults who are overweight or have obesity. The main goal was to check safety and side effects, and to measure how the drug moves through the body. Participants were randomly assigne…

This early-phase study tested a new drug called LY3484356 in 87 postmenopausal women with early-stage, hormone-receptor-positive breast cancer. The goal was to see if the drug is safe and how it affects cancer cells before the participants had surgery. The study lasted up to 2.5 …

This study tested a connected insulin management platform in 36 people with type 1 or type 2 diabetes who use insulin. The goal was to see if the platform helped them take their insulin doses on time and keep their blood sugar in a healthy range. Participants used a continuous gl…

This study tested the long-term safety and effectiveness of lebrikizumab, a drug for moderate-to-severe atopic dermatitis (eczema). Over 1,100 participants who had already taken the drug in earlier studies were followed for up to 33 months. The goal was to see how well the drug c…

This Phase 3 trial tested the drug tirzepatide (a once-weekly injection) against a placebo in 206 Chinese adults with type 2 diabetes. The goal was to see if tirzepatide could safely lower blood sugar levels. Participants had to have stable weight and a BMI of 23 or higher. The s…

This study tested a once-daily pill called orforglipron in 546 adults with type 2 diabetes whose blood sugar was not well controlled despite using insulin (with or without other diabetes medications). The goal was to see if adding orforglipron could safely lower blood sugar level…

This study tested a new once-daily pill called orforglipron against an existing drug, dapagliflozin, in adults with type 2 diabetes whose blood sugar was not well controlled with metformin alone. About 962 participants took either orforglipron or dapagliflozin for roughly 46 week…

This early-stage study tested whether adding a new drug (LY3841136) to an existing weight-loss medication (tirzepatide) is safe and tolerable. 96 healthy overweight or obese adults took part over about 42 weeks. The main goal was to check for side effects, not to prove weight los…

This phase 2 trial tested an oral drug called LY3972406 in 33 adults with moderate-to-severe plaque psoriasis. The study compared the drug to a placebo to see if it could reduce skin symptoms. Results will help determine if larger studies are warranted.

This study tested the safety of Lyumjev, a rapid-acting insulin, in 150 adults with type 2 diabetes in India. Participants used Lyumjev along with their usual long-acting insulin for 26 weeks. The main goal was to see how many people had low blood sugar episodes. The study is alr…

This study tested a medication called tirzepatide in children and teenagers aged 10 to 17 with type 2 diabetes. Participants were already taking metformin or insulin but still had high blood sugar. The goal was to see if tirzepatide could safely lower blood sugar levels better th…

This phase 3 study tested a new once-daily pill called orforglipron against an existing oral semaglutide in nearly 1,700 adults with type 2 diabetes whose blood sugar was not well controlled on metformin. The main goal was to see how well orforglipron lowers blood sugar levels ov…

This early-stage study tested a new drug called LY3437943 in 85 people with obesity. Participants received either the drug or a placebo, and researchers measured how many calories they ate and how their bodies used energy. The goal was to see if the drug could help control appeti…

This phase 3 study tested an experimental once-daily pill called orforglipron (LY3502970) against a placebo in 1613 adults who are overweight or have obesity and type 2 diabetes. The goal was to see if the drug helps with weight loss and improves blood sugar control. Participants…

This completed phase 1 study tested whether a weekly injection of retatrutide helps people with type 2 diabetes recover faster from low blood sugar (hypoglycemia). 80 participants on metformin and diet/exercise received either retatrutide or a placebo for 16 weeks. Researchers me…

This study tests whether the drug mevidalen can safely improve thinking, memory, and daily function in people with mild-to-moderate Alzheimer's disease. About 300 participants will receive either mevidalen or a placebo for 26 weeks. The main goal is to see if the drug eases sympt…

This early-stage study tested a new drug called LY3532226 in 132 people with obesity to see if it is safe and how the body processes it. Participants received weekly or monthly doses, and researchers monitored side effects and drug levels in the blood. The goal was to gather safe…

This phase 3 study tested a weekly injection called retatrutide in 445 people who are overweight or have obesity and also have knee osteoarthritis. The goal was to see if it reduces knee pain and helps with weight loss. Participants received either the drug or a placebo for about…

This study tested the safety of a new drug called LY3841136, given alone or with another drug (tirzepatide), in 128 Japanese adults who are obese or overweight. Researchers monitored side effects and how the body processes the drugs over several months. The goal was to see if the…

This early-phase trial is testing a new drug called LY4005130 in 118 healthy volunteers to see if it is safe and how the body processes it. Participants receive either the drug or a placebo, given as an injection under the skin or into a vein. The study focuses on side effects an…

This study looked at how the body processes a drug called LY4064809. Seven healthy adults received the drug by mouth and by IV to compare how much enters the bloodstream. The goal was to understand the drug's absorption, not to treat any disease. Participants stayed at a research…

This study looked at how the drug LY3502970 behaves in people with healthy kidneys compared to those with kidney problems. Researchers measured how much drug gets into the blood and how fast the body clears it. The goal is to understand if kidney impairment changes drug levels, w…

This early-stage study tested a new oral drug called LY3502970 in 26 healthy adults. The goal was to see how quickly the drug enters the bloodstream and how long it takes the body to clear it, comparing different pill versions. Participants took multiple doses over several weeks,…

This completed Phase 1 study enrolled 120 healthy volunteers to measure how much olomorasib enters the bloodstream and how quickly the body eliminates it. Participants took a single dose of the drug by mouth and stayed overnight at the research center for 10 nights over about 7 w…

This study looked at how the drug quinidine changes the amount of orforglipron in the blood of 27 healthy adults. Participants took both drugs by mouth, and researchers measured drug levels over time. The goal was to understand how the body processes these drugs together, not to …

This study looked at how two different versions of the drug LY3502970 behave in the body. Thirty-nine healthy adults took part to help researchers measure drug levels in the blood and check for any safety issues. The goal was to gather information, not to treat a disease.

This study looked at how the antibiotic clarithromycin changes the amount of LY3502970 in the blood of 26 healthy adults. Participants took LY3502970 alone and then with clarithromycin to see if there is a drug interaction. The study was completed and lasted about 85 days per per…

This study looked at how the drug LY3502970 enters the bloodstream and leaves the body in people with different levels of liver function. 29 participants, including healthy volunteers and those with mild to severe liver impairment, took a single dose. The goal was to understand d…

This early-stage trial tested an experimental oral drug called LY3502970 in 34 healthy adults. Researchers measured how much of the drug gets into the blood and how the body processes it, both after eating and on an empty stomach. The main goals were to check safety and understan…

This completed phase 1 study looked at how the drug cyclosporine changes the levels of an experimental drug called LY3502970 in the blood. Thirty-two healthy adults took LY3502970 alone and then with cyclosporine. The goal was to understand the interaction, not to treat any disea…

This completed Phase 1 study in 10 healthy adults measured how much of the drug LY3502970 enters the bloodstream after being taken by mouth compared to directly into a vein. The goal was to understand the drug's absorption and breakdown in the body. Results will guide dosing for …

This early-stage study gave a single radioactive dose of the experimental drug LY3502970 to 6 healthy men. Researchers measured how much of the drug appeared in blood, urine, and stool over time to understand how the body absorbs and eliminates it. The study is complete and does …

This completed Phase 1 study looked at how orforglipron, an experimental drug, changes the way the body processes several common medications (digoxin, simvastatin, rosuvastatin, acetaminophen, and midazolam) in 50 healthy overweight or obese adults. The goal was to measure drug l…

This completed phase 1 study looked at how the antifungal drug fluconazole changes the way the body handles the experimental cancer drug olomorasib. Fifteen healthy volunteers took olomorasib alone and then with fluconazole, and researchers measured drug levels in their blood. Th…

This study looked at how the drug LY3537031 moves through the body in people with different levels of kidney function. It included 31 adults with normal kidneys, kidney impairment, or end-stage kidney disease. The goal was to measure drug levels in the blood and how long it takes…

This completed Phase 1 study looked at how the drug LY3537982 is processed in people with different levels of kidney function. Researchers compared 32 participants with normal kidneys, moderate kidney problems, and severe kidney problems. The goal was to see how kidney impairment…

This study looked at how two different versions of the drug LY4064809 enter the bloodstream and how long the body takes to remove them. It involved 24 healthy adults who stayed at a research center for about a month. The goal was to gather information, not to treat any disease.

This early-stage study tested the safety and tolerability of a new drug called LY4060874 in 121 healthy adults. Participants were monitored for side effects and how the drug moved through their bodies. The study did not aim to treat any disease, but to gather important safety inf…

This completed Phase 1 trial tested the drug LY4268989 (MORF-057) in 144 healthy volunteers, including Japanese and Chinese participants. The main goals were to measure how the body absorbs and processes the drug, check for side effects, and see how food or other drugs (like mida…

This early-stage trial tested the safety and tolerability of an experimental drug called LY3985863 in 24 healthy Chinese participants. The drug was given as an injection under the skin, and researchers monitored side effects and how the body processed the drug. Since this study w…

This completed Phase 1 study tested two different ways to give the drug remternetug: an auto-injector and a prefilled syringe. 72 healthy volunteers received a single injection to see how much drug gets into the blood and how fast the body clears it. The goal was to compare the t…

This study looked at how two different capsule forms of the drug olomorasib are absorbed into the blood, and whether food changes that absorption. It involved 191 healthy Japanese participants over about 6 weeks. The goal was to gather information, not to treat any disease.

This early-phase study tested a drug called LY4064809 in 10 healthy Chinese adults. The main goal was to see how much of the drug gets into the blood and how fast the body gets rid of it. Researchers also checked for safety and side effects. The study lasted about 21 days and the…

This study looked at how well two different autoinjectors deliver the drug mirikizumab into the bloodstream of healthy people. About 500 healthy adults received a single injection under the skin using either a standard 1-mL autoinjector or a newer 2-mL version. The goal was to se…

This completed phase 1 study looked at how imlunestrant, a potential cancer drug, affects the body's handling of other medications like repaglinide, omeprazole, and dextromethorphan. It also tested how quinidine changes imlunestrant levels. 113 healthy women of non-childbearing p…

This completed Phase 1 study looked at how food and other medications (omeprazole, itraconazole, carbamazepine, and midazolam) affect the levels of the experimental drug LY3484356 in the blood of 82 healthy women who cannot become pregnant. The goal was to measure how the body ab…

This completed Phase 1 study in 16 healthy adults looked at whether taking multiple doses of selpercatinib (a cancer drug) changes how the body processes repaglinide (a diabetes medication). Participants received both drugs in a fixed order, and researchers measured drug levels i…

This study looked at how a drug called LY3484356 enters the bloodstream and leaves the body. Sixteen healthy women who cannot become pregnant took a single dose with a radioactive tracer. Researchers measured the drug in blood, urine, and stool to understand its absorption and el…

This completed Phase 1 study looked at how imlunestrant, an oral drug, enters the bloodstream and leaves the body in women with and without liver impairment. 27 female participants took a single dose, and researchers measured drug levels over time. The goal is to understand if li…

This completed phase 1 study in 20 healthy women of non-childbearing potential looked at how repeat doses of imlunestrant, an experimental cancer drug, affect the body's ability to process midazolam, a common sedative. Participants took both drugs orally, and researchers measured…

This study tested a new drug called LY3522348 in 65 healthy people to see if it is safe and what side effects it might cause. Researchers also checked how the drug enters the blood and how long the body takes to get rid of it. The study had two parts, lasting up to about 6 to 8 w…

This study looked at how the drug selpercatinib changes the way the body handles midazolam, a common sedative. Sixteen healthy adults took both drugs, and researchers measured drug levels in the blood. The goal was to gather safety and interaction data, not to treat any disease.

This study tested how healthy adults absorb different forms of bimagrumab, given alone or together with tirzepatide. The goal was to compare the body's concentration of these drugs, not to treat any disease. 125 healthy participants took part, and the study lasted about 4.5 month…

This early-stage study tested a single oral dose of LY3526318 in 16 healthy women to see how it affects blood flow in the skin after exposure to cinnamaldehyde (a compound in cinnamon). The goal was to understand the drug's basic effects, not to treat any disease. The study is co…

This early-stage study tested a new drug called LY3876602 in 74 healthy volunteers to see if it is safe and how the body handles it. Participants received either the drug or a placebo by IV, and researchers measured how much drug got into the blood and spinal fluid. The study is …

This completed Phase 1 study looked at how olomorasib, an oral drug, enters the bloodstream and leaves the body in people with mild, moderate, or severe liver impairment compared to healthy volunteers. 46 participants received a single dose. The goal is to understand if liver fun…

This study looked at how two common drugs—itraconazole (an antifungal) and rifampin (an antibiotic)—change the way the body processes selpercatinib, a cancer medication. Twenty-four healthy adults took selpercatinib alone and then with each of the other drugs. Researchers measure…

This completed Phase 1 study looked at how food and the heartburn drug omeprazole affect the absorption of selpercatinib, a cancer medication. Twenty healthy adults took selpercatinib under different conditions—with a high-fat meal, on an empty stomach, and after taking omeprazol…

This study looked at how the body processes the drug selpercatinib (LOXO-292) in people with different levels of kidney function. Researchers gave a single dose to 37 volunteers—some with healthy kidneys and some with kidney impairment—and measured drug levels in the blood and ur…

This completed Phase 1 study looked at whether a single dose of selpercatinib, a cancer drug, changes the heart's electrical activity (QT interval) in 32 healthy adults. Participants received selpercatinib, a placebo, or a control drug (moxifloxacin) in a crossover design. The ma…

This study looked at how the cancer drug selpercatinib changes the levels of rosuvastatin, a cholesterol-lowering drug, in the blood. It involved 28 healthy adults and lasted about 26 days. The goal was to understand any drug interactions and check safety when both are taken toge…

This early-stage study tested an experimental drug called LY3526318 in 16 healthy adults to see how the body absorbs and removes it, and whether it is safe. Participants received either single or multiple doses by mouth. The study was completed and no treatment for any disease wa…

This early-stage study tested a new drug, LY3985297, in 140 healthy volunteers to see if it is safe and how the body processes it. Participants received either a single dose or multiple doses of the drug or a placebo, given through a vein or under the skin. The study is complete …

This early-stage study tested the safety and tolerability of a single dose of lebrikizumab in 24 healthy Chinese adults. Half received the drug and half received a placebo, with researchers monitoring side effects and how the drug enters and leaves the body. The study is complete…

This early-stage trial tested the safety and how the body handles a new drug called LY3451838 in 53 healthy adults. Participants received either a single dose of the drug into a vein or under the skin, or a placebo. The main goal was to check for side effects and measure drug lev…

This early-stage study tested several new versions of insulin lispro in 54 healthy volunteers to see how quickly the body absorbs and clears them, and whether they are safe. Participants received one or more injections, and researchers measured insulin levels in the blood. Becaus…

This completed Phase 1 study looked at how healthy male volunteers absorb, break down, and eliminate the experimental drug LY4065967. Sixteen participants received the drug by mouth and by IV, and researchers measured levels in blood, urine, and stool. The goal was purely to unde…